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Conclusion: In selected NSCLC patients with localised or locally ad-
vanced tumours deemed too large for curative treatment, chemotherapy 
may reduce tumour volume sufﬁciently to allow radical RT to be given. 
Survival and local relapse rates are comparable to patients treated with 
primary radiotherapy in published studies. 
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Introduction: The treatment of choice for patients with inoperable, 
locally too extensive non-small cell lung cancer (NSCLC) is radiother-
apy with the aim of palliation thoracic symptoms. There is no strong 
evidence that any regimen gives greater palliation and least toxicity, but 
the typical standard schedule in many Institutions is 30Gy in 10 frac-
tions over two weeks.
Purpose: To investigate, whether the shorter course of 20Gy in 5 frac-
tions over one week is comparable to standard schedule for symptom 
control and survival.
Material and Methods: A total of 67 patients with symptomatic inop-
erable locally advanced non small cell lung cancer were included. 30 
patients (arms A) received 30Gy in 10 fractions over two weeks and 37 
patients (arms B) with 20Gy in 5 fractions over one week. All patients 
were treated through anteroposteriorly opposing portal in Linear accel-
erator. The ﬁeld included the loco regional tumour volume with margin 
of not more 1cm. The major clinical characteristics and the incidence 
and degree of initial disease related symptoms in both groups were 
similar. 85% patients had dyspnoea 59, 7% cough, 44, 7% haemoptysis 
and 34, 3% chest pain. Treatment effects were assessed using scoring 
of symptomatic changes and by chest X-Ray or CT. 
Results: No signiﬁcant differences between study arms were observed 
in the degree of relief of cough, dyspnoea, chest pain, and haemopty-
sis. Palliation of symptoms was achieved in high rates in both group 
of patients: 78, 2% for pain (80% A / 77% B), 76, 6% for haemoptysis 
(78,5A / 75% B), 35% for dyspnoea (34, 6%A / 35, 4%B), and 40 % 
for cough (38, 8%A /40, 9%B). There were no differences between two 
arms in survival. 
Treatment was well tolerated in both arms .The most frequent adverse 
event was oesophagitis grade 2.
Conclusion: The short regimen of 20Gy in ﬁve fractions provide 
equivalent survival and effective palliation of tumour related symptoms 
in the patients with symptomatic inoperable locally advanced non small 
cell lung cancer The short regimen had social and economic advan-
tages compared with standard regimen and suggest its usefulness in the 
routine management
P3-182 NSCLC: Radiation Posters, Wed, Sept 5 – Thurs, Sept 6 
Effect of prophylactic cranial irradiation after complete 
resection of Non-small cell lung cancer
Jung, Sung Soo1 Joung, Mi-Kyong1 Lee, Yu-Jin1 Lee, Jeong Eun1 Park, 
Hee-Sun2 Kim, Ju Ock2 Kim, Sun Young2 
1 Chungnam National University Hospital and Cancer Research Insti-
tute, Dae-jeon, Korea 2 Department of Internal Medicine, Chungnam 
National University Hospital & Cancer Research Institute, Dae-jeon, 
Korea 
Background: In stages l-lllA non-small cell lung cancer (NSCLC), 
after complete resection the primary tumor, brain metastases account 
for 9.4-36.8% of all recurrence. The possible usefulness of prophylactic 
cranial irradiation (PCI), suggested by studies in small cell lung carci-
noma. But the beneﬁt of PCI in NSCLC is controversial. We evaluated 
effect of PCI after complete resection of non-small cell lung cancer lllA 
and lllB. 
Methods: A retrospective review was performed of 50 patients who 
received a chemotherapy and surgery with stage lllA and lllB NSCLC 
seen between January, 2000 and September, 2005 at Chungnam na-
tional university. There were 25 patients (50%) in the PCI group and 
25(50%) in the non-PCI group. All patients performed brain CT or MRI 
before PCI. There were no brain metastases at the time of initial evalu-
ation. PCI was delivered in 15 (30GY) fraction size over 3 weeks in the 
25 patients.
Results: The median duration of follow-up was 24.5months (6-66 
months). The incidence of brain metastasis in the PCI group was 2 case 
(8%) compared with the non-PCI group was 4 case (16%) (p=0.38). 
The brain metastasis-free survival in the PCI group were 27months 
(9-66 month) and in the non-PCI group were 21 months (4-58 month) 
(p=0.02). The median survival time in the PCI group were 27 months 
(10-66 month) and in the non-PCI group were 24 months (6-58 month) 
(p=0.02). No major treatment-related toxicity was observed.
Conclusions: PCI improved both overall survival and brain-metastasis 
free survival among patients with stage lllA and lllB NSCLC in our 
study. PCI may be effective combination treatment for locally advanced 
non-small cell lung cancer. 
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Background: Radiation Esophagitis (RE) is one of the most com-
mon acute toxicity in lung cancer treatment especially in concurrent 
chemoradiation (CCRT). It reduces patients’ Quality of Life during the 
treatment and remains the important dose limiting factor. Some clinical 
predictors and relating parameters of Dose Volume Histogram (DVH) 
for RE were reported, however, those were not established.
Methods: The record of 17 lung cancer patients treated with CCRT in 
our hospital between April 2005 and February 2007 were reviewed. 
DVH parameters were calculated by Exio Version 4.2.1 (CMS). The 
parameters analyzed included length of esophagus irradiated, the per-
centages of esophagus volume receiving 5Gy (V5), 10Gy (V10), 15Gy 
(V15), 20Gy (V20), 25Gy (V25), 30Gy (V30), 40Gy (V40), 50Gy 
(V50), 60Gy (V60), mean and maximum dose of esophagus, perfor-
mance status, age, Brinkman index, hemoglobin, total protein(TP) and 
lactate dehydrogenase. RE was scored by common terminology criteria 
for adverse events version 3.0. Mann-Whitney U-test was used for 
statistical analysis. 
Results: The median age was 66 years old (55 - 74). All chemothera-
peutic regimens contain platinum agents. Twelve (71%) patients devel-
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oped grade 2 RE, and no one developed grade 3 or more. V5-60 were 
plotted according to grade of RE(ﬁg). V15 (p=0.04), V20 (p=0.03), 
V25 (p=0.03), V30 (p=0.03) and TP (p=0.04) were signiﬁcantly associ-
ated with the development of grade 2 RE.
Conclusions: Esophagus volume received low dose irradiation like 
under V30 and TP might be predictors of RE. 
P3-184 NSCLC: Radiation Posters, Wed, Sept 5 – Thurs, Sept 6 
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Purpose: Retrospective analyses were performed on the patients with 
primary or metastatic lung cancer, who were treated with hypofraction-
ated stereotactic radiation therapy (HSRT).
Patients and Methods: HSRT was applied to 34 patients who were 
unﬁt for either surgery or other systemic therapy since Jan. 1994 till 
Oct. 2006: 14 were with primary lung cancer at cT1~2N0 stages; 20 
were with metastasis. All patients received 5 consecutive daily fractions 
after 3-dimensional conformal planning, and the total doses were 50 
Gy (by 10 Gy/fraction) to 7 patients, and 60 Gy (by 12 Gy/fraction) to 
the remaining 27 patients. The median follow-up period was 13 months 
(range, 2~66 months). Clinical response was evaluated by chest CT in 
one month of HSRT, and the impacts of possible prognostic factors on 
local control and overall survival were evaluated. 
Results: Radiologic complete response was achieved in seven patients 
(20.6%): one in 50 Gy arm (14.3%); six in 60 Gy arm (22.2%). Local 
control and overall survival of all patients at 2 years were 88.4% and 
46.9%. On univariate analyses, tumor size larger than 3 cm was sig-
niﬁcantly adverse factor with respect to local control at 2 years (95.4% 
vs 0%, p=0.02), while lesion nature (primary vs metastatic, p=0.81), 
radiation dose (50 Gy vs 60 Gy, p=0.57), and tumor location (periph-
eral vs central, p=0.28) were not signiﬁcant. No factor had signiﬁcant 
impact on overall survival (Table 1,2). Even though there was one fatal 
acute pneumonitis superimposed on COPD in 60 Gy arm, all acute and 
chronic lung toxicities were grade I or II, and there was no signiﬁcant 
relationship between radiation dose and lung toxicity.
Conclusion: In HSRT for small lung lesion, tumor size was the most 
important factor with respect to local control.
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Purpose: Although radiotherapy (RT) improves locoregional control 
and survival in patients with lung cancer, radiation pneumnitis (RP) is 
a common treatment related toxicities. It has been proposed that serial 
measurement of plasma cytokine level can be valuable to estimate risk 
of radiation pneumonitis. Aim of this study was to evaluate the relation 
to the level of serial measurement of plasma cytokines and the develop-
ment of RP and dose volume parameters in 3-D RT plan.
Method and Materials: This prospective study enrolled 30 lung 
cancer patients irradiated with curative intent. Minimum follow-up du-
ration was more than 6 months. Plasma sample obtained before, weekly 
during RT and at 2, 4 weeks follow-up visit after RT. Cytokine analysis 
was performed for IL-1α, IL-6, TNF-αand TGF-β1 using enzyme 
linked immunosorbant assay. All the included patients were treated 
with 3-D conformal RT and dose volume histogram analysis were 
performed. Patients were assessed at each follow-up visit for sign and 
symptoms of RP. RP was determined on the basis of radiologic change 
or symptom of RP scored by RTOG toxicity criteria. We analyzed the 
correlation of symptomatic RP with potential predictive factors (age, 
gender, histology, stage, performance status, underlying lung disease, 
pretreatment pulmonary function test, tumor location, chemotherapy 
or not, chemotherapy regimen or timing, total radiation dose, radiation 
ﬁeld size, fraction size, V20, V30, mean lung dose) and plasma level of 
IL-1α, IL-6, TNF-α and TGF-β1. Univariate and multivariate analyses 
were performed to assess the relationship with RP. 
Results: Overall 8 patients (26.7%) developed RP. Three (10.0%) pa-
tients had grade 3 or higher RP. The multivariate analysis revealed the 
MLD, V20, V30 were the only signiﬁcant factors for symptomatic RP 
occurrence (p<0.05). No associations were found between base line cy-
tokine levels and the risk of RP. IL-6 levels were higher before, during, 
and end of RT in patients with radiation pneumonitis (mean value in RP 
vs non-RP; 35.45 pg/ml vs 15.15 pg/ml, p<0.05) Even though plasma 
level of pre-RT TGF-β1 in RP patients was higher than in non-RP 
patients, it was not statistically signiﬁcant. In patients not developing 
RP, plasma level of TGF-β1 decreased during RT and remained stable 
after RT, however, patients suffering RP had elevated TGF-β1 level 
at the end of RT. These difference of TGF-β1 dynamics between RP 
non-RP patients were marginally signiﬁcant at the end of RT (p=0.06). 
Interestingly, the level of TGF-β1 at the end of RT were associated with 
dosimetric factors such as MLD, V20, V30. Other cytokines, level of 
IL-1α, TNF-α showed stable during whole course of RT and no mean-
ingful changes in association with RP.
Conclusion: The results of our study did not conﬁrm that increase level 
of cytokines are independent signiﬁcant predictive factors for RP pre-
diction in multivariate analysis. Howerver, mean IL-6 level and level 
of TGF-β1 at the end of RT were associated RP occurrence and other 
dosimetric factors.
